{"id":2377,"date":"2019-10-05T21:59:40","date_gmt":"2019-10-05T19:59:40","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2377"},"modified":"2024-06-26T12:11:46","modified_gmt":"2024-06-26T10:11:46","slug":"tumour-angiogenesis","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/tumour-angiogenesis\/","title":{"rendered":"Tumour Angiogenesis"},"content":{"rendered":"\n

\n\t\tTumour angiogenesis\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\tOur research group at the ProCURE Program (Catalan Institute of Oncology) and OncoBell Program (IDIBELL) is focused on determining the consequences of adaptation and resistance to anti-angiogenic cancer therapy. For that we use translational research in murine models of cancer, particularly Kindey Cancer PDOX models and NeuroEndocrine transgenic models to study in vivo mechanisms of adaptation to anti-angiogenics, and validate our findings using clinical samples from our hospital and collaborating institutions.
\nOur scientific achievements have been published in prestigious journals in the field of cancer research with numerous “preview”, “highlight” or commentary articles in high impact scientific journals. Furthermore, we have an important international position in the field of antitumor therapies and angiogenic resistance mechanisms.\n

144<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"blood_vessels-mip\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tMechanisms of resistance to antiangiogenic therapies.
\nTherapeutic studies in Kidney Cancer murine models, both PDOX and syngenic.
\nTherapeutic studies in pancreatic NeuroEndocrine tumors.
\nDiscovery of non-invasive biomarkers in clinical trials with antiangiogenics.\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Ligero M, Hernando J, Delgado E, Garcia-Ruiz A, Merino-Casabiel X, Ibrahim T, Fazio N, Lopez C, Teul\u00e9 A, Valle JW, Tafuto S, Custodio A, Reed N, Raderer M, Grande E, Garcia-Carbonero R, Jimenez-Fonseca P, Garcia-Alvarez A, Escobar M, Casanovas O, Capdevila J & Perez-Lopez R., Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial<\/strong>., British Journal of Cancer Reports, 2023, doi:10.1038\/s44276-023-00010-0<\/p>\n

Peix,F;Casanovas,O, Promalignant effects of antiangiogenics in the tumor microenvironment<\/strong>., Semin. Cancer Biol., 2022;86(Pt 3):199-206, doi:10.1016\/j.semcancer.2022.03.003<\/p>\n

S\u00e1nchez Guix\u00e9,M;Hierro,C;Jim\u00e9nez,J;Viaplana,C;Villacampa,G;Monelli,E;Bras\u00f3 Maristany,F et al, High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer<\/strong>., Clin. Cancer Res., 2022;28(1):137-149, doi:10.1158\/1078-0432.CCR-21-1810<\/p>\n\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t